Schering files to trade on New York Stock Exchange

Article

For the last 11 years Schering AG has been represented in the U.S. by its subsidiary, contrast agent manufacturer Berlex Laboratories, but the German parent company will soon be listed on the New York Stock Exchange.The move is being made to broaden

For the last 11 years Schering AG has been represented in the U.S. by its subsidiary, contrast agent manufacturer Berlex Laboratories, but the German parent company will soon be listed on the New York Stock Exchange.

The move is being made to broaden Schering’s shareholder base in the U.S., according to Dr. Giuseppe Vita, chairman of the company’s board of executive directors, who hopes it will lure more talent to the company’s subsidiaries in the U.S.

“The NYSE listing will permit us to introduce a stock-based compensation program in the United States,” Vita said, “thus enabling us to continue to attract and retain high-caliber talent.”

Vita will step down as chairman in April 2001 and will be succeeded by Dr. Hubertus Erlen.

Schering has not previously operated under its own name in the U.S. During World War II, the U.S. seized German companies such as Schering, which a guardian management operated until 1971. At that time Schering AG signed an agreement with spin-off Schering-Plough that the parent company would not do business in the U.S. market under its German name, and it became Berlex labs in the U.S.

In addition to contrast agents, Berlex and other U.S. subsidiaries of Schering manufacture vascular and MR injection systems, radiopharmaceuticals, hormones, anti-inflammatory agents, oral contraceptives, and various agricultural products.

The contrast media industry is competitive. X-ray and CT contrast media are experiencing price declines brought on in part by generic contrast agents supplanting brand agents, price pressure forcing large discounts, and less expensive locally manufactured agents limiting revenue (SCAN, 8/2/00). Sales of MR and ultrasound media, on the other hand, are growing.

Schering is among the major vendors of contrast agents, which include Bracco, Mallinckrodt, and Nycomed Amersham.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.